Clinical Trials in Dallas

Showing 1521-1540 of 15,003 trials

Foregut Leaks-Role of Microbiome

NCT07424469

Aims 1. To understand the microbial composition involved with foregut leaks 2. To define the virulence changes in the microbiota following foregut leaks 3. To identify host response mechanisms and how they change with interventions 4. Utilize this information to improve patient outcomes

Gastrointestinal Diseases

Baylor Research Institute50 participantsStarted Aug 2020

Dallas, Texas, United States

RECRUITINGPhase 1/2< 1 mile

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

NCT05616793

The goals of this clinical trial are assess the natural course of LCA5-IRD over 6 months and to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration due to biallelic mutations in the LCA5 gene. Funding Source- FDA Office of Orphan Products Development (OOPD).

LCA5

Opus Genetics, Inc22 participantsStarted Jun 2023

Philadelphia, Pennsylvania, United States • Dallas, Texas, United States

COMPLETEDNA< 1 mile

Brain Enhancement Training Towards Elders Resilience to Aging, Phase IIB

NCT05599490

This study aims to examine the longer-term benefits of a novel, neuroplasticity-based, computerized and web-deliverable training program (PACR-CT) five years from the initial 10 weeks of training from our Phase II study - Protocol #: PSC-0605-17 (Aim 1) and test the interactive effect of previous training and 10 weeks of booster training (Aim 2). Both the study and the software being investigated meet the criteria of Non-Significant Risk.

Age-related Cognitive Decline

Posit Science Corporation135 participantsStarted Dec 2023

Iowa City, Iowa, United States • Dallas, Texas, United States

Foregut Leaks-Role of Microbiome

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

Brain Enhancement Training Towards Elders Resilience to Aging, Phase IIB

Find Trials by Condition in Dallas

RPMO2 Oximeter Accuracy During Sleep 1 Trial

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

A Study to Train a Machine Learning Algorithm for an Evaluation of the Use of Biometric Data Captured at the Wrist for the Identification of Acute Opioid Use Events and the Quantification of Opioid Withdrawal in Opioid Dependent Individuals

CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy

DAY101 In Gliomas and Other Tumors

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer